27 Consistent with these findings, a large global retrospective cohort study involving over 5 million individuals with obesity across 17 countries supported the neuroprotective potential of semaglutide in people with obesity, revealing reduced rates of AD (relative risk [RR] of 0.627), Lewy body dementia (RR of 0.59), vascular dementia (RR of 0.438), and PD (RR of 0.574)
Patients with type 2 diabetes are at increased risk of NAION as a result of their condition
For the kidneys, this means improved filtration efficiency, reduced scarring, and enhanced regenerative capacity, offering hope for managing conditions like chronic kidney disease and mitigating age-related organ decline (6)
Potential Medication Reduction Weight loss with Semaglutide might allow you to reduce or even stop taking antihypertensive medications, lipid/cholesterol-lowering drugs, and glucose control medications
Sharing a few of my reflections from the LinkedIn studio in the clip below